History

1997	Start of publicly sponsored BMBF-Project „Development of a novel wound dressing for burns” at Europe’s leading institute for textile research ITV Denkendorf.
2001	Foundation of Polymedics Innovations GmbH by the five leading scientists who developed SUPRATHEL® and other tissue engineering technologies.
2001	CE mark and launch of SUPRATHEL® in Germany and Austria.
2004-2009	International Expansion and regulatory approvals in Switzerland, Nordics, UK, Italy, Turkey, South Africa, Mexico, Pakistan, Australia.
2004-2009	International Expansion and regulatory approvals in Switzerland, Nordics, UK, Italy, Turkey, South Africa, Mexico, Pakistan, Australia.
2009	US – FDA 510K approval.
2010	KFDA approval in Korea. Inauguration of state of the art in-house production in Denkendorf, Germany.
2015	Foundation of US subsidiary Polymedics Innovations Inc. Today PMI develops and manufactures new technologies for the wound care sector in Denkendorf and markets its products in 30 countries around the world.
2016	Opening of US subsidiarity in Woodstock, Georgia.
2017	SUPRA SDRM® 510k certification in the United States.
2019	SUPRA SDRM® product approval in the European Union. Cooperation with PolyNovo Biomaterials Pty Ltd. for the distribution of NovoSorb® BTM in the DACH (Germany, Austria, Switzerland) region.
2020	Christian Planck appointed as Co-CEO of PolyMedics Innovations GmbH alongside Prof. Dr. Heinrich Planck. PMI expands the distribution of NovoSorb® BTM to Benelux and Sweden.
2021	Product launch of the novel synthetic guided wound closure matrix SUPRA SDRM®CW for difficult to heal wounds.